Home › Companies › X4 Pharmaceuticals, Inc. › 2025-2026
At X4 Pharmaceuticals, Inc.'s shareholder meeting held May 11, 2026, in the 2025-2026 proxy season, 59 asset managers reported how they voted in their SEC Form N-PX filings, covering 219 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — X4 Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: X4 Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 12, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and X4 Pharmaceuticals, Inc.’s Form 8-K, filed May 12, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 11, 2026: 5 items on X4 Pharmaceuticals, Inc.’s Form 8-K, filed May 12, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore X4 Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are X4 Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Gary J. Bridger, Ph.D. | 72,863,269 | -- | -- | 3,510,134 | 6,474,104 | 95% | Not verified | — |
| Elect Director: Françoise De Craecker | 73,419,383 | -- | -- | 2,954,020 | 6,474,104 | 96% | Not verified | — |
| Elect Director: Michael S. Wyzga | 71,679,834 | -- | -- | 4,693,569 | 6,474,104 | 94% | Not verified | — |
| 2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 | 82,734,674 | 68,992 | 43,841 | -- | -- | 99.9% | Approved | — |
| 4. Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers | 70,932,142 | 5,420,569 | 20,692 | -- | 6,474,104 | 93% | Approved | — |
Source: X4 Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 12, 2026 — read the filing on EDGAR.
Each item below shows how the 59 asset managers that disclosed a X4 Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of X4 Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors for terms expiring in 2029: Francoise De Craecker
X4 Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Françoise De Craecker”): 73,419,383 for, 2,954,020 withheld, per its Form 8-K filed May 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 16,063,959 for, 9,081 withheld, 7,170 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,870,658 | 0 | 0 | 0 | For |
| Vanguard | 3,283,741 | 0 | 5,717 | 0 | For |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 66,731 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 8,654 | Withhold |
| John Hancock | 0 | 0 | 1,453 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 425 | Withhold |
| ProShares | 0 | 0 | 0 | 2 | Withhold |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors for terms expiring in 2029: Gary J. Bridger, Ph.D.
X4 Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Gary J. Bridger, Ph.D.”): 72,863,269 for, 3,510,134 withheld, per its Form 8-K filed May 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 16,063,958 for, 9,081 withheld, 7,171 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,870,658 | 0 | 0 | 0 | For |
| Vanguard | 3,283,740 | 0 | 5,718 | 0 | For |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 66,731 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 8,654 | Withhold |
| John Hancock | 0 | 0 | 1,453 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 425 | Withhold |
| ProShares | 0 | 0 | 0 | 2 | Withhold |
Combines 5 wordings of this item as funds reported it.
99.5% of fund votes cast · no official result
The 9 asset managers below reported 15,994,573 for, 78,465 withheld, 7,172 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,870,658 | 0 | 0 | 0 | For |
| Vanguard | 3,281,086 | 0 | 5,719 | 2,653 | For |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 66,731 | Withhold |
| Victory Capital | 0 | 0 | 0 | 8,654 | Withhold |
| John Hancock | 0 | 0 | 1,453 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 425 | Withhold |
| ProShares | 0 | 0 | 0 | 2 | Withhold |
Combines 2 wordings of this item as funds reported it.
52.5% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve the second amendment and restatement of the X4 Pharmaceuticals, Inc. 2017 Equity Incentive Plan, increasing the number of shares available for issuance under the plan.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 8,870,658 | 0 | 0 | Against |
| Vanguard | 3,823 | 3,285,634 | 0 | 0 | Against |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 66,731 | 0 | 0 | Against |
| Victory Capital | 0 | 8,654 | 0 | 0 | Against |
| Vericimetry Funds | 6,601 | 0 | 0 | 0 | For |
| John Hancock | 0 | 1,453 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 425 | 0 | 0 | Against |
| ProShares | 0 | 2 | 0 | 0 | Against |
Fund voting reports, all 10 managers: 3,853,253 for, 12,233,557 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Saturn V Capital Management LP | 6,456,646 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 3,233,743 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 9,690,389 for.
Combines 6 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
X4 Pharmaceuticals, Inc.’s own tally for this item (“4. Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers”): 70,932,142 for, 5,420,569 against — passed, per its Form 8-K filed May 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4. | Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers The Company’s stockholders approved, by a non-binding “say-on-pay” vote, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy s…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,103,400 | 767,258 | 0 | 0 | Mixed |
| Vanguard | 3,286,798 | 2,660 | 0 | 0 | For |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 66,731 | 0 | 0 | Against |
| Victory Capital | 0 | 8,654 | 0 | 0 | Against |
| Vericimetry Funds | 6,601 | 0 | 0 | 0 | For |
| John Hancock | 0 | 1,453 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 425 | 0 | 0 | 0 | For |
| ProShares | 0 | 2 | 0 | 0 | Against |
Fund voting reports, all 10 managers: 15,240,053 for, 846,758 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morgan Stanley | 9,079,045 | 0 | 0 | 0 | For |
| Fidelity | 8,103,400 | 0 | 0 | 0 | For |
| Saturn V Capital Management LP | 6,456,646 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 6,314,452 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 4,436,310 | 0 | 0 | 0 | For |
| Kalehua Capital Management LLC | 3,722,840 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 3,233,743 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 2,571,478 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,233,742 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,832,566 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 1,670,468 | 0 | 0 | 0 | For |
| Blackstone Inc. | 0 | 1,501,695 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 915,159 | 0 | 0 | Against |
| BlackRock | 0 | 904,595 | 0 | 0 | Against |
| Woodline Partners LP | 846,927 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 615,649 | 0 | 0 | 0 | For |
| Vanguard | 513,710 | 9,456 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 408,979 | 0 | 0 | 0 | For |
| State Street | 378,381 | 10,953 | 0 | 0 | For |
| Venrock Adviser, LLC | 270,890 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 225,194 | 0 | 0 | Against |
| Northern Trust | 0 | 178,235 | 0 | 0 | Against |
| Affinity Asset Advisors, LLC | 135,951 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 73,264 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 66,734 | 0 | 0 | Against |
Institutional-manager reports, all 53 managers: 52,909,436 for, 3,954,393 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the selection of PricewaterhouseCoopers LLC as the Company's independent registered public accounting firm for the year ending December 31, 2026.
X4 Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026”): 82,734,674 for, 68,992 against — passed, per its Form 8-K filed May 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2. | Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Direc…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 16,086,811 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,870,658 | 0 | 0 | 0 | For |
| Vanguard | 3,289,458 | 0 | 0 | 0 | For |
| Morgan Stanley | 2,333,406 | 0 | 0 | 0 | For |
| Equitable | 1,509,423 | 0 | 0 | 0 | For |
| Charles Schwab | 66,731 | 0 | 0 | 0 | For |
| Victory Capital | 8,654 | 0 | 0 | 0 | For |
| Vericimetry Funds | 6,601 | 0 | 0 | 0 | For |
| John Hancock | 1,453 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 425 | 0 | 0 | 0 | For |
| ProShares | 2 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 94,319,696 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.40% |
| 2 | Vanguard | 3.49% |
| 3 | Morgan Stanley | 2.47% |
| 4 | Equitable | 1.60% |
| 5 | Charles Schwab | 0.07% |
| 6 | Victory Capital | <0.01% |
| 7 | Vericimetry Funds | <0.01% |
| 8 | John Hancock | <0.01% |
| 9 | Advisors' Inner Circle Fund III | <0.01% |
| 10 | ProShares | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Morgan Stanley | 9.63% |
| 2 | Fidelity | 8.59% |
| 3 | Saturn V Capital Management LP | 6.85% |
| 4 | PERCEPTIVE ADVISORS LLC | 6.69% |
| 5 | Deep Track Capital, LP | 4.70% |
| 6 | Kalehua Capital Management LLC | 3.95% |
| 7 | NEA Management Company, LLC | 3.43% |
| 8 | Trails Edge Capital Partners, LP | 2.73% |
| 9 | BVF INC/IL | 2.37% |
| 10 | Samsara BioCapital, LLC | 1.94% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Funds managed by Empery Asset Management, LP | 9.64% | DEF14A |
| Empery Asset Management, LP | 9.59% | 13G |
| Morgan Stanley | 8.70% | 13F |
| FMR (Fidelity) | 8.59% | 13F |
| Perceptive Advisors LLC | 8.57% | 13G |
| Deep Track Capital, LP | 8.53% | 13G |
| Entities affiliated with Bain Capital Life Sciences Investors, LLC | 8.42% | DEF14A |
| BCLS II Equity Opportunities, LP | 7.47% | 13G |
| Coastland Capital Partners LP | 7.47% | DEF14A |
| Saturn V Capital Management LP | 6.82% | 13G |
Percentages above are of 94,319,696 shares outstanding, as reported by X4 Pharmaceuticals, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from X4 Pharmaceuticals, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
X4 Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “X4 Pharmaceuticals (XFOR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/x4-pharmaceuticals-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.